Octozi offers a human-in-the-loop AI platform that integrates with existing clinical systems to automate data cleaning, reconciliation, review, and reporting for clinical trials. The platform combines large language models, deterministic clinical algorithms, and external medical knowledge to produce context-aware outputs and keeps clinical teams in oversight. Octozi already supports Phase III trials and, in a controlled study, its AI assistance increased data-cleaning throughput roughly six-fold while cutting reviewer error rates from 54.7% to 8.5% and reducing false positive queries about fifteen-fold. An economic analysis cited in the announcement estimated more than $5 million in savings for a representative Phase III oncology trial. The company is headquartered in New York City and recently raised a $3 million seed round to support its growth.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2026